The CRF₁ receptor antagonist SSR125543 prevents stress-induced long-lasting sleep disturbances in a mouse model of PTSD: comparison with paroxetine and d-cycloserine.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Behavioural Brain Research

• Publication date

  2015-02-15

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.bbr.2014.11.006PMID 25446760
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans.

  2014cited by this paper
• Does D-Cycloserine Enhance Exposure Therapy for Anxiety Disorders in Humans? A Meta-Analysis

  2014cited by this paper
• D-Cycloserine Augmentation of Exposure Therapy for Post-Traumatic Stress Disorder: A Pilot Randomized Clinical Trial

  2014cited by this paper
• The CRF1 receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and d-cycloserine

  2013cited by this paper
• Effect of D‐cycloserine in conjunction with fear extinction training on extracellular signal‐regulated kinase activation in the medial prefrontal cortex and amygdala in rat

  2013cited by this paper
• A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder.

  2012cited by this paper
• The CRF₁ receptor antagonist SSR125543 attenuates long-term cognitive deficit induced by acute inescapable stress in mice, independently from the hypothalamic pituitary adrenal axis.

  2012cited by this paper
• A Randomized Placebo-Controlled Trial of d-Cycloserine to Enhance Exposure Therapy for Posttraumatic Stress Disorder

  2012cited by this paper
• Treating nightmares and insomnia in posttraumatic stress disorder: a review of current evidence.

  2012cited by this paper
• Antagonizing corticotropin-releasing factor in the central nucleus of the amygdala attenuates fear-induced reductions in sleep but not freezing.

  2011cited by this paper
• Acute inescapable stress exposure induces long-term sleep disturbances and avoidance behavior: a mouse model of post-traumatic stress disorder (PTSD).

  2011cited by this paper
• Central deficiency of corticotropin-releasing hormone receptor type 1 (CRH-R1) abolishes effects of CRH on NREM but not on REM sleep in mice.

  2010cited by this paper
• Conditional corticotropin-releasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleep

  2009cited by this paper
• Impact of Sleep Disturbances on PTSD Symptoms and Perceived Health

  2009cited by this paper
• Disturbed sleep in post-traumatic stress disorder: secondary symptom or core feature?

  2008cited by this paper
• Elevated plasma corticotrophin-releasing hormone levels in veterans with posttraumatic stress disorder.

  2008cited by this paper
• Contextual fear extinction ameliorates sleep disturbances found following fear conditioning in rats.

  2008cited by this paper
• Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD

  2008cited by this paper
• Sleep Disturbances in Patients with Post-Traumatic Stress Disorder

  2006cited by this paper
• Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine.

  2006cited by this paper
• Hippocampal synaptic plasticity and spatial learning are impaired in a rat model of sleep fragmentation

  2006cited by this paper
• Disaster-related posttraumatic stress symptoms and sustained attention: evaluation of depressive symptomatology and sleep disturbances as mediators.

  2005cited by this paper
• D-cycloserine facilitates extinction of learned fear: effects on reacquisition and generalized extinction.

  2005cited by this paper
• Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression.

  2004cited by this paper
• Strain differences in the influence of open field exposure on sleep in mice.

  2004cited by this paper
• D-cycloserine and the facilitation of extinction of conditioned fear: consequences for reinstatement.

  2004cited by this paper
• Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.

  2004cited by this paper
• Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies

  2003cited by this paper
• Paroxetine for the treatment of sleep disturbance in posttraumatic stress disorder

  2002cited by this paper
• The effect of sleep fragmentation on daytime function.

  2002cited by this paper
• 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization.

  2002cited by this paper
• Sleep disturbances in the wake of traumatic events.

  2001cited by this paper
• Stress in the brain.

  2000cited by this paper
• Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder.

  1999cited by this paper
• Rat strain differences suggest a role for corticotropin-releasing hormone in modulating sleep.

  1997cited by this paper
• Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder.

  1997cited by this paper
• Sleep restoration as a function of periodic awakening, movement, or electroencephalographic change.

  1987cited by this paper
• Down-regulation of neural corticosterone receptors by corticosterone and dexamethasone.

  1985cited by this paper

• Sleep phenotyping in a rat model of susceptibility to substance use disorders

  2025cites this paper
• Insomnia-related rodent models in drug discovery

  2024cites this paper
• The Evolving Role of Animal Models in the Discovery and Development of Novel Treatments for Psychiatric Disorders.

  2023cites this paper
• Pharmacological strategies for post-traumatic stress disorder (PTSD): From animal to clinical studies.

  2022cites this paper
• CRF-R1 Antagonist Treatment Exacerbates Circadian Corticosterone Secretion under Chronic Stress, but Preserves HPA Feedback Sensitivity

  2021cites this paper
• Cannabinoids as therapeutics for PTSD.

  2020cites this paper
• A novel arousal-based individual screening reveals susceptibility and resilience to PTSD-like phenotypes in mice

  2020cites this paper
• Prefrontal cortex rTMS reverses behavioral impairments and differentially activates c-Fos in a mouse model of post-traumatic stress disorder.

  2019cites this paper
• Increased 5-HT2C receptor editing predisposes to PTSD-like behaviors and alters BDNF and cytokines signaling

  2019cites this paper
• Bmal1 knockdown suppresses wake and increases immobility without altering orexin A, corticotrophin‐releasing hormone, or glutamate decarboxylase

  2018cites this paper
• Control of Stress-Induced ACTH Secretion by Vasopressin and CRH: Additional Evidence

  2016cites this paper
• Role of neuroinflammation and sex hormones in war-related PTSD.

  2016cites this paper
• The CRF System as a Therapeutic Target for Neuropsychiatric Disorders.

  2016cites this paper
• Sleep and REM sleep disturbance in the pathophysiology of PTSD: the role of extinction memory

  2015cites this paper